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The arbovirus, Venezuelan equine encephalitis virus (VEE), causes disease in humans and equines during periodic
outbreaks. A murine model, which closely mimics the encephalitic form of the disease, was used to study mechanisms of
attenuation. Molecularly cloned VEE viruses were used: a virulent, epizootic, parental virus and eight site-specific glyco-
protein mutants derived from the parental virus. Four of these mutants were selected in vitro for rapid binding and
penetration, resulting in positive charge changes in the E2 glycoprotein from glutamic acid or threonine to lysine (N. L. Davis,
N. Powell, G. F. Greenwald, L. V. Willis, B. J. Johnson, J. F. Smith, and R. E. Johnston, Virology 183, 20–31, 1991). Tissue culture
adaptation also selected for the ability to bind heparan sulfate as evidenced by inhibition of plaque formation by heparin,
decreased infectivity for CHO cells deficient for heparan sulfate, and tight binding to heparin–agarose beads. In contrast, the
parental virus and three other mutants did not use heparan sulfate as a receptor. All eight mutants were partially or
completely attenuated with respect to mortality in adult mice after a subcutaneous inoculation, and the five mutants that
interacted with heparan sulfate in vitro had low morbidity (0–50%). These same five mutants were cleared rapidly from the
blood after an intravenous inoculation. In contrast, the parental virus and the other three mutants were cleared very slowly.
In summary, the five VEE viruses that contain tissue-culture-selected mutations interacted with cell surface heparan sulfate,
and this interaction correlated with low morbidity and rapid clearance from the blood. We propose that one mechanism of
f the vattenuation is rapid viral clearance in vivo due to binding o
INTRODUCTION
Venezuelan equine encephalitis virus (VEE), an alpha-
virus in the togavirus family, is a single-stranded, posi-
tive-sense RNA virus. The alphavirus genome is encap-
sidated by the capsid protein and surrounded by a highly
structured envelope (Paredes et al., 1993) consisting of
two membrane glycoproteins, E1 and E2 (Rice and
Strauss, 1982). E2 is the putative viral attachment protein
for VEE (Roehrig et al., 1988) and, thus, interacts with the
host cell.
The interaction of virus with its host cell receptor is
one of the important factors dictating host and tissue
tropism. VEE and other arboviruses cycle between mos-
quitoes and mammals in nature. VEE therefore has
evolved to use either a universally conserved receptor or
multiple receptors in its disparate hosts. Furthermore,
VEE has evolved to infect a variety of tissues. In the
mosquito, VEE infects the mesenteron, fat body, nerves,
brain, and salivary glands (Weaver, 1986). In vertebrate
hosts, VEE is both lymphotropic and neurotropic (Victor
et al., 1956; Gleiser et al., 1961; Jahrling and Scherer,
1973a; de la Monte et al., 1985). The mammalian receptor
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for VEE remains unknown, but a laminin-binding protein
was identified as the putative host cell receptor for VEE
in mosquito cell culture (Ludwig et al., 1996). A similar
molecule on mammalian cells, the high-affinity laminin
receptor, was suggested as a receptor for another alpha-
virus, Sindbis virus (SIN) (Wang et al., 1992). SIN can also
interact with heparan sulfate (HS) on mammalian cells
(Mastromarino et al., 1991; Byrnes and Griffin, 1998; Klim-
stra et al., 1998). However, Klimstra et al. (Klimstra et al.,
1998) demonstrated for SIN that HS binding is a cell
culture adaptation and is correlated with attenuation in
mice. Thus, we postulated that HS also may play a role
in VEE binding and pathogenesis in vivo.
Heparan sulfate is a glycosaminoglycan (GAG). GAGs
consist of repeating disaccharide units that are heterog-
enously sulfated, and they covalently bind to protein
cores to form proteoglycans. Proteoglycans are ubiqui-
tous on the cell surface and in the extracellular matrix.
One function of proteoglycans is to bind a variety of
ligands, e.g., laminin, fibroblast growth factor, antithrom-
bin III, and superoxide dismutase (Zhou et al., 1992). The
most common GAGs are heparan sulfate, chondroitin
sulfate, and dermatan sulfate (Kjellen and Lindahl, 1991).
The first virus shown to interact with cell surface HS
was herpes simplex virus (WuDunn and Spear, 1989).
Several other herpesviruses also interact with HS, in-
cluding pseudorabies virus, cytomegalovirus, and bovine
0042-6822/00 $35.00
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resultiherpesvirus types 1 and 4 (Mettenleiter et al., 1990;
kazaki et al., 1991; Neyts et al., 1992; Kari and Gehrz,
992; Vanderplasschen et al., 1993). Recent studies have
shown that many other viruses interact with HS in cell
culture, but the functional significance of HS binding for
non-cell culture adapted viruses has not always been
determined. These viruses include adenoassociated vi-
rus (AAV), vaccinia virus, human papillomavirus, human
immunodeficiency virus (HIV), foot-and-mouth disease
virus (FMDV), respiratory syncytial virus, porcine repro-
ductive and respiratory syndrome virus, equine arteritis
virus, and dengue virus (Patel et al., 1993; Jackson et al.,
1996; Asagoe et al., 1997; Chen et al., 1997; Jusa et al.,
1997; Krusat and Streckert, 1997; Chung et al., 1998;
Summerford and Samulski, 1998; Joyce et al., 1999).
Many of these viruses use other cell receptors in
addition to HS. Herpesviruses bind a second receptor
(Montgomery et al., 1996; Warner et al., 1998; Geraghty et
al., 1998). HIV uses CD4 and a chemokine coreceptor
(Dalgleish et al., 1984; Berger et al., 1999), and FMDV
uses integrin as its receptor (Neff et al., 1998). Alternative
cell receptors have recently been postulated for AAV
(Qing et al., 1999; Summerford et al., 1999). Several au-
thors have proposed a model where initial binding to HS
is followed by binding and entry via a coreceptor (Patel et
al., 1993; Spear, 1993; Summerford et al., 1999). In other
viral systems, HS may serve as an alternate receptor,
and its use is dependent on the cell type and viral strain.
Ibrahim et al. (Ibrahim et al., 1999) found that HIV uses
HS on cell lines, but not on primary lymphocytes. HS
usage is a tissue culture adaptation for FMDV (Sa-Car-
valho et al., 1997; Baranowski et al., 1998; Escarmis et al.,
1998; Neff et al., 1998) and SIN (Klimstra et al., 1998). In
other words, the wild-type viruses do not bind HS, but
use an alternate receptor exclusive of GAG binding.
T
Amino Acid Changes in the Gly
VEE
clonea
E3
56–59 3 4 76
V3000 RKRR E E E
V3010 RKRR E E K
V3012 RKRR E E E
V3014 RKRR E E E
V3026 RKRR K K E
V3032 RKRR E E E
V3034 RKRR E E E
V3526 Db E E E
V3533 RKRR E E K
a All clones are isogenic except at the noted loci.
b D, deletion of the furin cleavage site (amino acids 56 to 59 of E3),
94 BERNARD, KLIMSFurthermore, adaptation to tissue culture and HS usage
is correlated with attenuation for FMDV (Sa-Carvalho etal., 1997; Neff et al., 1998) and SIN (Klimstra et al., 1998,
1999; Byrnes and Griffin, 2000).
Our laboratory has developed a panel of VEE mutants,
which were selected for rapid binding and penetration in
tissue culture (Johnston and Smith, 1988; Davis et al.,
1991). The SIN mutants that were studied by Klimstra et
al. (Klimstra et al., 1998) were similarly selected and were
found to use HS as a receptor; therefore, we hypothe-
sized that the VEE mutants would also use HS. In this
study, we found that the VEE tissue-culture-adapted mu-
tants, which have a net positive charge change in the E2
glycoprotein, interacted with cell surface HS. In contrast,
the wild-type virus and three other VEE glycoprotein
mutants did not. Furthermore, HS interaction in vitro
correlated with low morbidity in vivo and rapid clearance
of virus from the blood of mice, suggesting a mechanism
of attenuation.
RESULTS
The genotypes of the viruses used in this study are
shown in Table 1. All of the mutants are attenuated
relative to the parental virus (Table 2). Although the
mortality for V3034 was not statistically different from that
of V3000 for this experiment, the mortality was statisti-
cally different for a previous experiment (P , 0.001)
(Grieder et al., 1995). Furthermore, we have inoculated
over 80 mice with V3000 using the same experimental
conditions and have not observed a survivor (Davis et al.,
1995; Grieder et al., 1995; Aronson et al., 2000; R. E.
Johnston et al., unpublished observations), supporting
our conclusion that V3034 is attenuated.
Four of the VEE mutants (V3010, V3012, V3014, and
V3026) were selected on BHK cells for rapid binding and
penetration (Johnston and Smith, 1988). All four of these
viruses have an amino acid change in the E2 glycopro-
in Sequences of VEE Mutants
E1
120 209 239 253 272
T E I F A
T E I F A
K E I F A
T K N F T
T E I F A
T K I F A
T E I F T
T E I S A
T E I F A
ng in an E3–E2 fusion protein.
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TRA, Atein to a positively charged lysine (Davis et al., 1991). The
mutant V3026 has two contiguous codons with both
GWITHchanged to lysine. The mutant V3014 has three muta-
tions; two mutations (E2 209 and E1 272) are attenuating,
and one mutation (E2 239) has no effect on virulence
(Grieder et al., 1995). Each attenuating mutation also is
represented alone as a single mutant (V3032 and V3034).
Another tissue-culture-selected mutant, V3010, is limited
in spread beyond the draining lymph node after SC
inoculation of adult mice (Grieder et al., 1995). Aronson et
al. (Aronson et al., 2000) selected for revertants of V3010
in adult mice, and the mutant V3533 is a second-site
revertant that spreads beyond the draining lymph node,
but remains attenuated with respect to mortality. This
reversion restores the net charge of E2.
The mutant V3526 has a lethal deletion in the furin
cleavage site at the C-terminus of E3 paired with a
mutation in E1 that restores infectivity for BHK cells. In
contrast to the parental virus, V3000, for which E3 is fully
cleaved from E2, the V3526 construct results in an E3–E2
fusion protein incorporated into an infectious virion
(Davis et al., 1995). The other seven mutants listed in
Table 1 had the parental phenotype of complete cleav-
age of E3 from E2 (data not shown).
Inhibition of VEE infectivity by heparin
The tissue-culture-selected mutants are altered in
their interaction with the cell surface (Johnston and
Smith, 1988). Since all the mutants have amino acid
changes in E2 to a lysine (Davis et al., 1991), one poten-
tial explanation for the in vitro phenotype is an interaction
of the basic amino acid(s) in E2 with negatively charged
GAGs on the cell surface. Competition assays were
performed to determine the infectivity of each virus in the
presence of heparin (a highly sulfated, secreted form of
HS), chondroitin sulfate B, and dextran sulfate. All five
TABLE 2
Morbidity and Mortality of VEE Viruses after SC Inoculation
VEE clone
Morbidity
(No. sick/No. mice)
Mortality
(No. dead/No. mice)
V3000 8/8 8/8
V3010 0/8 0/8*
V3012 4/8 2/8**
V3014 0/8 0/8*
V3026 0/8 0/8*
V3032 2/8 1/8***
V3034 7/8 5/8†
V3526 0/8 0/8*
V3533 8/8 0/8*
Note. Adult mice were inoculated subcutaneously in the left rear
footpad with 103 PFU of virus. Results of a one-sided Fisher’s exact test
comparing the mortality of each group to the parental virus, V3000,
were *P , 0.0001, **P 5 0.0035, ***P 5 0.0007, †P 5 0.1.
INTERACTION OF VEEviruses with tissue-culture-selected mutations (V3010,
V3012, V3014, V3026, and V3032) were inhibited by TGAGs. The IC50 was lowest for heparin (Table 3), and the
inhibition was dose dependent (Fig. 1). In contrast, the
parental virus and the other three mutants were not
inhibited (V3000, V3034, and V3533) or were inhibited
only at high concentrations (V3526) (Table 3). Of the two
attenuating mutations of V3014, only the lysine at posi-
tion 209 of E2 (V3032) was associated with heparin
sensitivity. Furthermore, the mutant V3010 was sensitive
to heparin, but its second-site revertant (V3533) was
resistant like the parental virus (Fig. 1).
Infectivity of VEE virus for GAG-deficient cells
The infectivity of five VEE mutants was reduced in the
presence of soluble heparin, suggesting that these vi-
ruses interact with cell surface GAGs. Alternatively, sol-
uble heparin might coat the virus and sterically prevent
TABLE 3
Glycosaminoglycan Inhibition of Viral Infectivity for BHK Cells
VEE clone
GAG IC50 (mg/ml)
a
Heparin
Dextran
sulfate
Chondroitin
sulfate B
V3000 .1000 .1000 .1000
V3010 3 45 350
V3012 75 30 .1000
V3014 20 45 400
V3026 3 200 300
V3032 15 500 200
V3034 .1000 .1000 .1000
V3526 350 500 .1000
V3533 .1000 .1000 .1000
Note. Plaque assays were performed with increasing amounts of
AG. The data are representative of three independent assays.
a Average of three wells.
FIG. 1. The effect of heparin on VEE virus infectivity. BHK cells were
infected with V3000 (), V3010 (E), or V3533 (F) in the presence of
variable concentrations of heparin. The percentage of no treatment
was determined as follows: (the number of viral plaques at the desig-
nated heparin concentration/the number of viral plaques without hep-
95HEPARAN SULFATEarin) 3 100%. Each data point is the average of three replicates 6 SD.
he data are representative of three independent assays.
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9 TRA, Athe virus from binding another receptor. To confirm that
the viruses were interacting with cell surface GAGs, we
tested their infectivity on GAG-deficient cells derived
from CHO-K1 cells. VEE replicon particles (VRP) (Pushko
et al., 1997), which undergo only one round of replication,
were used in these assays. These particles contain the
same replicon genome, but are coated with the different
envelope glycoproteins corresponding to the various
VEE mutants. The VRPs with mutant glycoproteins resis-
tant to heparin (V3000, V3034, V3526, and V3533) had an
approximately 2-fold decrease in infectivity for the GAG-
deficient cells compared to the parental CHO-K1 cells
(Fig. 2). In contrast, VRPs from viruses that were inhibited
by heparin (V3010, V3014, and V3032) had a 10- to 100-
fold decrease in infectivity. The reduced infectivity of
these VRPs occurred on both cell lines: pgsA-745, which
are deficient in all GAGs (Esko et al., 1985), and pgsD-
677, which have increased levels of chondroitin sulfate,
but are deficient in heparan sulfate (Lidholt et al., 1992).
Therefore, these results suggest that the tissue-culture-
adapted viruses interacted with cell surface heparan
sulfate. Furthermore, the use of VRP ensured that differ-
ences in infectivity were due to an early virus–cell inter-
action and were not due to differences in viral replica-
tion, maturation, or spread. Again, the second-site rever-
tant, V3533, had the parental phenotype. Note that two of
the viruses (V3012 and V3026) were not tested in this
assay.
Binding of VEE viruses to immobilized heparin
To confirm that VEE viruses can bind GAGs, radiola-
FIG. 2. The relative infectivity of VRP for GAG-deficient CHO cells.
he cells were infected with VRP containing the GFP-expressing rep-
icon (V5005) coated with the indicated glycoproteins (e.g., 3000). Solid
ars represent the infectivity for pgsA-745 (deficient in all GAGs), and
haded bars represent the infectivity for pgsD-677 (deficient in HS). The
elative infectivity was calculated as follows: (the number of cells
nfected for the indicated cell line/the number cells infected for the
arental CHO-K1 cells) 3 100%. The data are representative of two
ndependent assays.
6 BERNARD, KLIMSbeled viruses were tested for their ability to bind to
heparin–agarose beads. All nine viruses bound to theimmobilized heparin to varying degrees (Fig. 3). There
was no consistent correlation between the degree of
binding and the putative interaction with cell surface
heparan sulfate. There are at least two possible expla-
nations for the lack of correlation: (1) the heparin–aga-
rose bead displays a very dense group of negatively
charged molecules, allowing the positively charged E2
(France et al., 1979) to bind; (2) the radiolabeled viruses
were passaged once in tissue culture; therefore, these
populations may contain a subset of tissue-culture-se-
lected variants that bind variably to heparin. Such mu-
tants arise very early during passage of SIN on BHK cells
(Klimstra et al., 1998).
To distinguish the relative strength of heparin–agarose
binding, four of the viruses were eluted from the heparin–
agarose beads with increasing NaCl concentration.
V3000 and V3533, which were heparin resistant in the
competition assays, showed peak elution at 200 mM
NaCl. In contrast, V3012 and V3032, which were heparin
sensitive and interacted with cell surface heparan sul-
fate, showed peak elution at 350 and 450 mM NaCl,
respectively (data not shown), suggesting substantially
stronger HS binding.
In vivo phenotype of VEE mutants
The heparan sulfate interaction observed in vitro cor-
related with the in vivo phenotype of the viruses. The VEE
mutants were partially or completely attenuated in adult
mice after SC inoculation (Table 2). All five viruses that
interacted with cell surface heparan sulfate (V3010,
V3012, V3014, V3026, and V3032) resulted in low morbid-
ity (0–50%). These data suggested that the heparan sul-
fate interaction influenced attenuation. Since HS is ubiq-
uitous on mammalian cell surfaces, we postulated that
the interaction of virus with HS would result in rapid
clearance from the blood.
FIG. 3. The binding of radiolabeled virus to immobilized heparin. The
open bars represent the binding to heparin–agarose beads, and the
shaded bars represent the binding to BSA–agarose beads. Each bar
represents the average for two to seven independent assays with bars
ND JOHNSTONrepresenting high and low values for the individual assays. CPM is
counts per minute of radioactivity.
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WITHThe clearance of infectious virus from the blood was
measured after intravenous inoculation (Fig. 4). The vi-
ruses that did not interact with cell surface heparan
sulfate (V3000, V3034, V3526, and V3533) were cleared
very slowly from the blood, less than one order of mag-
nitude decline over 60 min. In contrast, all five viruses
that interacted with cell surface heparan sulfate were
cleared rapidly (two to five orders of magnitude decline).
The mutation at E2 209 from glutamic acid to lysine
FIG. 4. The clearance of VEE virus from serum after an intravenous
IV) inoculation. 1V 0 5 virus concentration in serum (PFU/ml) at time 0,
t 5 virus concentration in serum (PFU/ml) at time t(1, 5, 10, 30, or 60
in). Three mice per virus were inoculated IV with V3000 (, solid line),
3010 (E, solid line), V3012 (, solid line), V3014 (n , solid line), V3026
n , dashed line), V3032 (F, dashed line), V3034 (, dashed line), V3526
h, dashed line), or V3533 (F, solid line). Each data point is the average
f three mice 6 SD. The data are representative of two independent
ssays.
T
Viral Titers at 60
VEE clone
Log10
Serum Blood
V3000 7.5 7.3
(60.10) (60.12)
V3010 5.2 4.8
(60.40) (60.67)
V3012 4.9 4.8
(60.03) (60.02)
V3014 2.8 2.5
(60.22) (60.17)
V3026 4.6 4.4
(60.33) (60.15)
V3032 3.2 3.5
(60.84) (60.88)
V3034 6.4 6.3
(60.08) (60.20)
V3526 5.6 5.5
(60.79) (60.51)
V3533 6.9 6.8
(60.28) (60.18)
INTERACTION OF VEEa Average of three mice. Data are representative of two independent experconferred the most rapid clearance (Fig. 4, V3014 and
V3032). As was observed for the infectivity assays, the
single-site mutant V3010 and its second-site revertant,
V3533, revealed opposite phenotypes. V3010 was
cleared rapidly, while V3533, like the parent, was cleared
slowly.
The correlation between rapid clearance from the
blood and heparan sulfate interaction suggests that virus
was removed from the circulation by binding to tissues.
This hypothesis was supported by the data in Tables 4
and 5. For all the viruses, infectious virus was found after
60 min in the four organs examined: kidney, liver, lung,
and spleen (Table 4). However, the virus titer of an organ
represents the virus associated with tissue and the virus
in blood perfusing that organ. It was necessary, there-
fore, to determine whether the virus titer measured for
the various organs was due to virus in the blood or virus
associated with organ tissue. The organ blood volume
can be estimated as 18, 24, 32, and 50% for spleen,
kidney, liver, and lung, respectively (Altman and Dittmer,
1971). These values were used to estimate the amount of
virus attributable to the blood in each organ. The amount
of virus associated with organ tissue was then calcu-
lated as the virus titer in the organ minus the virus
predicted in the blood fraction. Substantial amounts of
infectious virus were found in at least one organ for all
nine viruses (Table 5). Virus titration does not account for
degraded virus or for virus in the eclipse phase of rep-
lication, but these data clearly demonstrate that the rap-
idly clearing viruses readily bind organ tissue. The virus
er IV Inoculation
titer) PFU/ml or PFU/g (6 SD)a
y Liver Lung Spleen
6.8 6.9 6.9
) (60.29) (60.11) (60.02)
3.5 5.0 6.4
) (60.78) (60.37) (60.01)
3.3 4.5 5.7
) (60.49) (60.22) (60.08)
4.1 3.5 4.5
) (60.43) (60.17) (60.17)
3.8 5.0 4.9
) (61.36) (60.72) (60.91)
3.2 4.2 5.3
) (60.86) (60.90) (60.25)
5.7 5.7 5.9
) (60.59) (60.11) (60.17)
4.4 4.3 6.0
) (60.37) (60.46) (60.14)
5.9 6.1 7.1
) (60.90) (60.25) (60.28)
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min aft
(virus
Kidne
7.4
(60.18
4.7
(60.18
4.6
(60.15
3.7
(60.24
5.1
(60.28
3.7
(61.15
6.0
(60.32
4.2
(60.31
6.8
(60.21iments.
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TRA, Atiters were determined at 60 min after inoculation before
viral replication and amplification could occur.
Alternatively, the differences in clearance kinetics
could have been explained by three trivial mechanisms.
First, the rapidly cleared viruses may have bound to the
cell fraction of blood, resulting in serum free of virus. This
mechanism was discounted because the serum and
whole blood titers for each of the viruses were equivalent
at the 60-min time point (Table 4). Note that the whole
blood was not treated with anti-coagulants, which can
interfere with binding. Second, the viruses may have
differed in how well they were recovered from serum or
blood. All nine viruses were spiked into serum or whole
blood (without anti-coagulant), and the percentage of
recovery did not vary significantly (data not shown). Fi-
nally, the rapidly cleared viruses may have been less
stable. This was examined in vitro by spiking serum- and
EDTA-treated blood with virus and measuring the virus
stability after 1 h at 37°C. All nine viruses were very
stable under these conditions with no significant decline
in titer (data not shown). Thus, since the recovery and
stability of the viruses were similar, we suggest that
rapid viral clearance from blood is correlated with effi-
cient binding to GAGs in tissues.
DISCUSSION
Using a cloned epizootic VEE strain and eight site-
specific glycoprotein mutants derived from it, we have
TABLE 5
Amount of Infectious Virus Associated with Organ Tissue and Not
Attributable to Virus in Blood Perfusing the Organ
VEE clone
Log10 (virus titer associated with organ tissue)
PFU/ga
Kidney Liver Lung Spleen
V3000 7.3 5.6 0b 6.5
V3010 4.4 0 4.8 6.4
V3012 4.4 0 3.6 5.7
V3014 3.7 4.2 3.5 4.6
V3026 5.1 4.6 5.3 5.5
V3032 4.5 3.3 4.7 5.3
V3034 5.9 4.2 0 5.6
V3526 0 0 0 5.6
V3533 6.8 4.4 0 7.1
Note. Viral titers were measured at 60 min after an IV inoculation
(Table 4).
a Virus titer associated with organ tissue was calculated as follows:
virus titer in organ at 60 min) 2 (virus titer in blood at 60 min 3 organ
lood fraction). Organ blood fraction was estimated as 18, 24, 32, and
0% for spleen, kidney, liver, and lung, respectively (Altman and Dittmer,
971).
b Negative values are reported as zero. Data are the averages for
three mice and are representative of two independent experiments.
98 BERNARD, KLIMSdemonstrated a genetic linkage among cell culture ad-
aptation, use of heparan sulfate as a predominant recep-tor, attenuation in a mouse model of VEE disease, and
acceleration of clearance from the circulation. The viru-
lent parental VEE and three of the mutants did not use
HS as a primary receptor in cell culture, suggesting that
VEE in nature uses another receptor. Furthermore, those
mutants that interacted strongly with HS still infected
cells deficient in HS, but with greatly decreased effi-
ciency. This indicates that, under these conditions, even
the HS binding mutants may have used the native recep-
tor. Similar results were observed for the related alpha-
virus, SIN (Byrnes and Griffin, 1998; Klimstra et al., 1998).
For VEE mutants selected for efficient growth in cell
culture, the ability to bind cell surface HS may function to
increase the contact between virus and cell, increasing
the probability that the virus will interact with the native
receptor. Similar models have been proposed by others
(Patel et al., 1993; Spear, 1993; Summerford et al., 1999).
Recent experiments with FMDV (Sa-Carvalho et al.,
997; Baranowski et al., 1998; Escarmis et al., 1998; Neff
et al., 1998) and SIN (Klimstra et al., 1998) suggest that
HS binding is a tissue culture adaptation, and our data
support this hypothesis. The VEE mutants that interacted
with HS were selected for rapid binding and penetration
on BHK cells (Johnston and Smith, 1988) and, thus, were
“tissue culture-adapted.” One of the SIN mutants (R114)
used by Klimstra et al. (Klimstra et al., 1998) was selected
in the same manner, and this mutant binds HS. One of
the tissue culture-adapted VEE mutants (V3012) has a
mutation at the same location as the attenuated VEE
vaccine strain, TC-83, which was passaged 83 times in
tissue culture (Berge et al., 1961). The mutation is at E2
position 120 from a threonine to a lysine or an arginine
for V3012 or TC-83 (Kinney et al., 1989), respectively. In
addition, another tissue-culture-adapted VEE mutant
(V3010) readily reverts to a non-HS binding phenotype in
vivo, by a same-site reversion to the V3000 codon or by
a second-site reversion from a lysine to glutamate
(V3533) (Aronson et al., 2000). This suggests that HS
binding is a selective advantage in tissue culture, but not
in the vertebrate host. Similar results were observed by
Byrnes and Griffin (Byrnes and Griffin, 2000), who iso-
lated SIN mutants upon passage of an HS-binding SIN in
mice. These mutants had a net decrease in the charge of
E2 and decreased HS binding. In addition, Sa-Carvalho
et al. (Sa-Carvalho et al., 1997) passed an HS-binding
FMDV variant in bovines. The variant reverted to wild
type or accumulated a second mutation in a neighboring
residue from a lysine to a glutamate.
The tissue culture adaptations that confer HS binding
for FMDV, SIN, and VEE are positive charge changes.
The FMDV mutations map to the viral surface (Sa-Car-
valho et al., 1997; Baranowski et al., 1998; Escarmis et al.,
1998), and the positively charged amino acids interact
with the negatively charged heparin (Fry et al., 1999) in a
ND JOHNSTONconformational rather than a linear domain. For SIN, both
conformational and linear heparin-binding sites were
WITHproposed (Klimstra et al., 1998). In contrast, none of the
VEE strains used in this study have a linear heparin-
binding domain in E2 as defined by others (Cardin and
Weintraub, 1989; Sobel et al., 1992; Hileman et al., 1998).
Thus, the VEE mutants presumably bind to HS via a
conformational domain. The mutations that confer HS
binding for SIN (Klimstra et al., 1998) and VEE are located
in similar positions on E2, suggesting several regions on
alphaviruses that interact with HS. The comparable E2
glycoprotein mutations are: (1) serine to arginine at po-
sition 1 for SIN vs glutamate to lysine at positions 3 and
4 for VEE (V3026); (2) glutamate to lysine at position 70
for SIN vs glutamate to lysine at position 76 for VEE
(V3010); (3) serine to arginine at position 114 for SIN vs
threonine to lysine at position 120 for VEE (V3012). A
fourth site was observed for VEE, but not SIN, at position
209 of E2 from a glutamate to a lysine (V3014 and V3032).
This site is in a VEE neutralization domain (Johnson et al.,
1990) and is exposed on the virion surface.
The importance of region 114 to 120 of E2 is further
exemplified by the second-site mutation of V3533—a
lysine to a glutamate at position 116. This mutation ab-
rogated HS binding when paired with the mutation at E2
76 (V3010) from a glutamate to a lysine. This suggests
that the amino acids at positions 76 and 116 in E2 may be
in close proximity on the virion surface and may partic-
ipate in a conformational HS-binding domain in the mu-
tant V3010, which has a lysine at both positions. In
addition, Byrnes and Griffin (Byrnes and Griffin, 2000)
have evidence that position 76 of E2 in SIN may act in HS
binding. When this amino acid was mutated from a lysine
to a glutamate, threonine, or asparagine, HS binding was
decreased.
Other VEE strains have positively charged amino acids
in the E2 regions proposed to be important in HS binding.
The VEE TC-83 vaccine strain has a mutation at E2
position 120 from a threonine to an arginine (Kinney et
al., 1989). Two monoclonal antibody resistant mutants of
TC-83 have two different mutations in E2—one at posi-
tion 182 from a serine to an arginine and another at
position 199 from a glutamate to a lysine (Johnson et al.,
1990). Several investigators have sequenced endemic
and epidemic strains of VEE. Two VEE IC strains have
two mutations in E2—a glycine to an arginine at position
193 and a threonine to an arginine at position 213 (Wang
et al., 1999). An outbreak strain of VEE IAB has a threo-
nine to lysine at position 205 of E2 (Kinney et al., 1992),
and a VEE II strain has a lysine at position 209 of E2
(Sneider et al., 1993). All four of these strains were
passaged in cell culture prior to sequencing; therefore, it
is possible that these mutations resulted from tissue
culture adaptation. Mutations that confer HS binding
arise very early during passage of SIN on BHK cells
(Klimstra et al., 1998).
INTERACTION OF VEEThe ability of the VEE mutants to interact with HS
correlated with attenuation in this study. This interaction,however, is not the only determinant of attenuation. One
of the non-HS binding mutants (V3526) was completely
avirulent. Attenuation of this mutant is likely due to de-
creased replication in vivo (N. L. Davis and R. E.
Johnston, unpublished observations). The mechanism for
partial attenuation of two other mutants (V3034 and
V3533) remains unknown. In another study, Kinney et al.
(Kinney et al., 1993) mapped the attenuating determi-
nants for the VEE vaccine strain, TC-83, to nucleotide 3 of
the 59 untranslated region and to E2 with the major
determinant being amino acid position 120 (Kinney et al.,
1993). Spotts et al. (Spotts et al., 1998) proposed that one
or both of these determinants results in sensitivity to
alpha/beta interferons. Our data suggest that HS inter-
action is a second mechanism of attenuation for TC-83.
The VEE mutant, V3012, has a single mutation at E2
position 120 from a threonine to a lysine. This VEE
mutant bound HS and was attenuated in adult mice. We
predict that TC-83, with the positively charged arginine at
E2 position 120, would also interact with HS.
Possible mechanisms of attenuation secondary to HS
interaction include inhibition of viral spread and increase
in viral clearance. Inhibition of spread from sites of rep-
lication may be due to nonproductive binding of virus to
HS on the infected cell, adjacent cells, or the extracellu-
lar matrix. Clearance from blood may be due to the
interaction of virus with HS in various tissues. Viral clear-
ance was examined in this study, and all five VEE mu-
tants that bound HS were rapidly cleared after an intra-
venous inoculation. Similar results were seen for an
HS-binding variant of SIN (Byrnes and Griffin, 2000). In
addition, the kinetics of clearance were similar to the
clearance of heparin-binding proteins (Wallinder et al.,
1984; Karlsson and Marklund, 1988; Yuge et al., 1997),
suggesting that rapid clearance was secondary to HS
interaction. The lysine at position 209 of E2 conferred the
most rapid clearance. This mutation also resulted in the
lowest infectivity for the heparan-sulfate-deficient CHO
cells, but there was no significant difference between the
five HS-binding mutants in the heparin competition and
binding experiments. This suggests that the HS-binding
VEE mutants differ in their qualitative and/or quantitative
binding to HS. Furthermore, the use of heparin in assays
does not delineate subtle differences in HS interactions.
Previous alphavirus studies have suggested that rapid
clearance is a mechanism of attenuation. Jahrling and
Scherer (Jahrling and Scherer, 1973b) found that avirulent
strains of VEE, including TC-83, were cleared rapidly
from blood, but virulent strains were cleared slowly after
intracardiac inoculation of hamsters. The clearance rates
were similar to those in this study. The blood titer of the
avirulent strains declined two to three orders of magni-
tude in 60 min, and the blood titer of the virulent strains
declined less than one order of magnitude. Similar re-
99HEPARAN SULFATEsults were observed in rhesus monkeys (Jahrling et al.,
1977a). In another study, six virulent VEE strains were
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three of six avirulent strains were cleared rapidly (Jahr-
ling et al., 1977b). This suggests, as in this study, that
rapid clearance is not the only mechanism of attenua-
tion. Another study used two plaque variants of the VEE
IAB Trinidad isolate, the genotypic background of the
wild-type virus used in this study (V3000). The benign
variant was cleared rapidly from hamster blood, and the
virulent variant was cleared slowly (Jahrling and Gorel-
kin, 1975). Rapid clearance from blood was also corre-
lated with attenuation for other alphaviruses—Western
equine encephalitis virus (Jahrling, 1976), Eastern equine
encephalitis virus (Marker and Jahrling, 1979), and SIN
(Postic et al., 1969; Byrnes and Griffin, 2000). The rapid
learance phenotype was associated with increased
inding to cells, agar, or hydroxylapatite (Schleupner et
al., 1969; Jahrling and Eddy, 1977; Marker and Jahrling,
1979).
Thus, rapid clearance from blood, secondary to alter-
ation in binding to HS, may play a general role in alpha-
virus attenuation, resulting in a lower and/or delayed
viremia and affecting viral spread throughout the host.
Studies are in progress to examine the effects of HS
binding on viremia and neuroinvasion.
MATERIAL AND METHODS
Cells
All cells were obtained from the American Tissue
Culture Collection. BHK-21 cells (ATCC CCL-10) were
maintained in alpha minimal essential medium (Gibco)
supplemented with 10% donor calf serum (DCS) and 10%
tryptose phosphate broth. The parental CHO-K1 cells
(ATCC CRL-61) and GAG-deficient derivatives were main-
tained in Ham’s F-12 medium (Gibco) supplemented with
10% fetal bovine serum. The two GAG-deficient CHO
mutants were deficient in all GAGs, pgsA-745 (ATCC
CRL-2242) (Esko et al., 1985), or only in heparan sulfate,
pgsD-677 (ATCC CRL-2244) (Lidholt et al., 1992).
Viruses
VEE and the site-directed mutant viruses were derived
from cDNA clones. The parental virus, V3000, is a mo-
lecular clone of the biological 1AB epizootic Trinidad
donkey isolate (Davis et al., 1989, 1991). The mutant
viruses are isogenic with the parental virus except at
defined loci in the glycoproteins (Table 1). The construc-
tion of the mutants was described previously (Davis et
al., 1991, 1995; Grieder et al., 1995; Aronson et al., 2000).
Virus stocks were made by in vitro transcription (Ambion)
of the cDNA plasmids, electroporation of RNA into BHK
cells, and collection of virus in supernatants at 24 h. The
electroporation supernatants were used directly without
100 BERNARD, KLIMSfurther tissue culture passage, except for the production
of radiolabeled virus as described below. The titers ofvirus stocks were determined by standard plaque assay
on BHK cells.
Replicon particles
VEE replicon particles were made using a split helper
system as described previously (Pushko et al., 1997). The
onstruction of the replicon genome (V5005) was also
escribed previously (Macdonald and Johnston, 2000). In
rief, the replicon genome contained the gene for the
reen fluorescent protein (GFP) mutant 2 (Cormack et al.,
996) in place of the VEE structural protein genes. The
lasmid with GFP mutant 2 was a generous gift from S.
alkow. The replicon genome was packaged in BHK
ells by supplying the VEE capsid and glycoproteins on
eparate helper RNA transcripts. VRP were made with
arental or mutant glycoprotein coats by using parental
r mutant glycoprotein helpers, respectively. Different
RP are denoted as V5005-3000, V5005-3010, V5005-
014, V5005-3032, V5005-3034, V5005-3526, and V5005-
533, signifying their replicon genome (V5005) and pa-
ental or mutant glycoprotein coat (-3000, -3010, etc.). The
iters of VRP stocks were determined by counting the
umber of GFP-expressing BHK cells with a FITC filter
et on a fluorescent microscope (Nikon) and were des-
gnated as infectious units per milliliter (IU/ml).
RP infectivity for GAG-deficient CHO cells
CHO-K1, CHO pgsA-745, and CHO pgsD-677 were
rown to subconfluency in 24-well tissue culture plates.
RP stocks were diluted in phosphate-buffered saline
PBS), pH 7.4, 1% DCS, 0.5 mM CaCl2, 0.5 mM MgCl2
(PBS diluent), to approximately 2 3 103 IU/ml. The same
inoculum (100 ml) was added to triplicate wells of each
cell line. The plates were incubated at 37°C, 5% CO2, for
1 h, medium was added, and the plates were then incu-
bated at 37°C, 5% CO2, for an additional 18 h. The
FP-expressing cells were counted using a FITC filter
et on a fluorescent microscope (Nikon).
nfectivity assays with glycosaminoglycans
Assays to determine the effects of heparin (Sigma),
hondroitin sulfate B (Sigma), or dextran sulfate (Sigma)
n viral infectivity were performed as described previ-
usly (Klimstra et al., 1998). Briefly, 200 PFU of virus was
ncubated with various concentrations of GAG in PBS
iluent for 30 min at 4°C, and then the virus–GAG mixture
as incubated with BHK cell monolayers for 60 min at
7°C, 5% CO2, prior to the addition of an agarose overlay.
laques were counted after incubation at 37°C, 5% CO2,
for 24 h. The 50% inhibitory concentration was defined as
ND JOHNSTONthe GAG concentration that inhibited 50% of plaque for-
mation compared to the no-GAG control.
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Virus was radiolabeled with [35S]methionine as de-
cribed previously (Klimstra et al., 1998). In brief, BHK
ells were inoculated with virus stocks at an m.o.i. of 5 to
0, and [35S]methionine was added at 6 h postinocula-
tion. Supernatants were harvested at 24 h postinocula-
tion. The radiolabeled virus was purified, using a 20–60%
sucrose discontinuous gradient, followed by a 20–60%
sucrose continuous gradient. The virus was concen-
trated by centrifugation through a 20% sucrose cushion,
and the pellets were resuspended in TNE buffer (50 mM
Tris, pH 7.2, 150 mM NaCl, 1 mM EDTA). All sucrose
solutions were made weight to volume in TNE buffer.
Virus binding assays
The attachment of radiolabeled virus to heparin–aga-
rose (Sigma) and bovine serum albumin–agarose
(Sigma) beads was assessed as described previously
(Klimstra et al., 1998). Briefly, radiolabeled virus was
diluted in PBS diluent to 1 3 105 CPM/50 ml. Fifty micro-
iters of diluted virus was added to 50 ml of washed
beads in duplicate or triplicate. The virus was incubated
with the beads for 60 min at 4°C. The beads then were
washed three times with 1 ml of PBS diluent and were
resuspended in 100 ml of TNE, 0.6% Nonidet P-40. Ra-
ioactivity associated with the beads was counted in
cintillation fluid using a beta-counter. Elution of bound
irus was performed using 50 mM step gradients of NaCl
n 10 mM phosphate, pH 7.4, from 100 mM to 1 M NaCl.
urine studies
Mice were housed in an environmentally controlled
oom in a BL-3 facility and were given food and water ad
ibitum. Female, outbred CD-1 mice (Charles River) were
btained at 5 weeks of age and were acclimatized for 1
o 2 weeks. All mice were between 6 and 7 weeks of age
t the start of the experiments.
The morbidity and mortality for each virus were deter-
ined by inoculating eight mice per group with 103 PFU
of virus subcutaneously in the left rear footpad. Mice
were evaluated clinically and weighed daily for 3 weeks.
Observed clinical signs included ruffled fur, paresis,
ataxia, hyperaesthesia, and circling. Morbidity was de-
fined as greater than 10% weight loss. A productive
infection was confirmed in all surviving mice by a posi-
tive antibody titer to VEE by ELISA or by protection from
V3000 challenge.
Studies to determine the clearance of virus from the
blood were performed as follows. All virus stocks used in
the clearance studies were concentrated by centrifuga-
tion through a 20% sucrose cushion (weight to volume in
TNE). The virus was resuspended in low endotoxin PBS,
INTERACTION OF VEE1% DCS (animal inoculation buffer), and stored at 280°C.
Virus was diluted in animal inoculation buffer immedi-ately prior to inoculation, and the remaining inoculum
was stored at 280°C. The titer of each inoculum was
confirmed and used to calculate the virus at time zero for
each mouse. Three mice per group were inoculated
intravenously (IV) in the lateral tail vein with 108 PFU of
irus in 100 ml. Mice were bled (20–50 ml) at 1, 5, 10, and
30 min postinoculation (p.i.) from the ventral tail artery. At
60 min p.i., the mice were euthanized, and blood, kidney,
liver, lung, and spleen were collected. Blood was allowed
to clot for 30–60 min at room temperature. Sera were
harvested after centrifugation for 10 min at 2000g. At the
60-min time point, a portion of the blood sample was not
processed for serum and was retained as whole blood.
PBS diluent was added to the organs to make a 10%
solution (weight to volume). All samples were frozen at
280°C prior to titration on BHK cells. Whole blood and
organ samples were homogenized after thawing. The
concentration of virus at time zero was calculated for
each mouse by dividing the inoculum dose (PFU) by the
total blood volume (ml) of each mouse. The total blood
volume (ml) was estimated by multiplying the weight (g)
of each mouse by 0.07 (Altman and Dittmer, 1971).
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